This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What’s underneath that macro “healthcare” index number of 67 is a precipitous decline in the past year for Americans’ trust in hospitals, compared with biotech, pharma, consumer healthcare, and even health insurance — all of which grew in trust between 2018 and 2019, but not so with the hospital segment of U.S.
There is one health care public policy issue that unites U.S. The macro-strategy for Optum is that, in their mission-words, “health care should be equally available to everyone, when and how they want it. In person, on the phone or online, quality health care is wherever you are,” their website informs us.
Health Populi’s Hot Points: The issue of drug and vaccine pricing for COVID-19 prevention and treatments has been under the media microscope since the start of the pandemic. Here’s one of many looks into the issue , in which I’m quoted on scenarios for Gilead’s possible pricing strategies for remdesivir.
When this occurred, it didn’t cause more than a ripple of interest outside biotech. She is the author of the recently-published book, HealthConsuming: From Health Consumer to Health Citizen. . She works with exceptional leaders seeking to build value in a transforming health care world. But the U.S.
.” Health Populi’s Hot Points: RealClear asked people to consult their forecasting tea leaves to consider which industries and organizations would improve the quality of health care for Americans 20 years into the future. That’s an interesting conundrum to consider.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content